Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
New Foot-And-Mouth Vaccine Is Safer and Cheaper to Produce
Mar 27, 2013
British scientists have developed a new vaccine against foot-and-mouth diseasethat is safer and easier to manufacture, an advance they believe should greatly increase production capacity and reduce costs.
The new vaccine does not require live virus in its production - an important consideration as foot-and-mouth disease (FMD) is extremely infectious and vaccine facilities handling virus samples are difficult to secure.
Experimental Vaccine Shows Promise for Ovarian Cancer
Apr. 8, 2013
Early results of a trial for a new personalized ovarian cancer vaccine offers hope for the large number of patients who relapse after treatment. Three-quarters of trial patients who received the new two-step immunotherapy appeared to respond to the treatment – one patient achieved complete remission.
H7N9 vaccine expected ready within 7 months: ministries
Apr. 9, 2013
As part of China's emergency response to the H7N9 bird flu on technological front, China formally launched a research project on Wednesday for developing a vaccine for H7N9.
Jointly launched by the Ministry of Science and Technology and the National Health and Family Planning Commission here, the move is expected to make a vaccine ready within seven months, an official statement said.
Novavax vaccine meets mid-stage trial goal, shares rise
Apr. 16, 2013
Novavax Inc said its vaccine to treat a virus that causes respiratory tract infections met the main goal, of immunizing women of childbearing age, in a mid-stage trial.
The vaccine against respiratory syncytial virus (RSV) could induce immune responses at levels that can protect infants through a transfer of antibodies from the mother, Novavax said citing trial.
Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe
Apr. 25, 2013
Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine, for primary and booster vaccination of infants from six weeks of age.
Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases.
Two doses of HPV vaccine not 3 may offer similar protection
Apr. 30, 2013
Two doses of the vaccine against human papilloma virus (HPV) may work just as well as the recommended three doses in protecting against infection, a new study from Canada suggests.
In the study, girls who received two doses of the HPV vaccine had just as good of an immune response to the vaccine as women who received three doses, even three years after vaccination. In studies of women, the HPV vaccine reduces the risk of developing early signs of cervical cancer and genital warts.
The new study is published today (April 30) in the Journal of the American Medical Association.
Dendreon's cancer vaccine sales drop as competition heats up
May 9, 2013
(Reuters) - Sales of Dendreon Corp's prostate cancer vaccine Provenge declined in the first quarter despite efforts by the biotechnology drugs maker to shore up flagging volumes.
The company's shares fell 14 percent to $4.06 in morning trade on the Nasdaq. They touched a low of $3.95.
Dendreon is watched closely due to the immense potential of cancer vaccines, but Provenge sales have never really taken off due to physician uncertainty about reimbursement and limited manufacturing capacity.
The emergence of newer prostate cancer drugs have also squeezed the vaccine's potential. Competing drugs, such as Medivation Inc's Xtandi and Johnson & Johnson's Zytiga, have the added advantage of being easier to use.
Results of the ROTAVAC Rotavirus Vaccine Study in India
May 15, 2013
The Government of India's Department of Biotechnology (DBT) and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India. Data from the trial, presented today at the International Symposium on Rotavirus Vaccines for India—The Evidence and the Promise, showed ROTAVAC to have an excellent safety and efficacy profile.
The clinical study demonstrates for the first time that the India-developed rotavirus vaccine ROTAVAC is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India. ROTAVAC significantly reduced severe rotavirus diarrhoea by more than half—56 percent during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause.
BravoBio attended Pathogen Clean Asia Summit 2013
May 16, 2013
On May 15 to May 16, BravoBio attended the Pathogen Clean Asia Summit 2013 held in Shanghai Marriott Hotel Luwan, China. The BD Director of BravoBio, Ms. Zhang Xiaoshu, was invited to be a speaker discussing the Pathogen Clean on the pharmaceutical industry.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next